林可霉素联合利巴韦林治疗小儿肺炎的临床疗效及安全性研究
|
摘要
目的探讨林可霉素联合利巴韦林治疗小儿肺炎的临床疗效及安全性。方法选取某院2016年7月～2018月7月的106例小儿肺炎进行研究,根据患儿病情的情况分为联合治疗组和单纯治疗组各53例,单纯治疗组采用利巴韦林治疗,联合治疗组在单纯治疗组的基础上进行林可霉素治疗,治疗1周时间,观察两组患儿的临床疗效、肺功能(FEV1/FVC、PEF和MBC)、炎性指标(IL-2、IL-6)及不良反应。结果联合治疗组的总有效率(96.4%)明显高于单纯治疗组(78.6%),有统计学意义(P<0.05);联合治疗组的FEV1/FVC、PEF和MBC水平比单纯治疗组明显增高(P<0.05);联合治疗组的IL-2、IL-6水平比单纯治疗组明显降低(P<0.05);两组患儿均无恶心、头疼、口干、嗜睡等药物不良反应。结论林可霉素联合利巴韦林治疗小儿肺炎可以有效改善患儿的肺功能,消除炎性反应,可以用于小儿肺炎的治疗。
OBJECTIVE To study the clinical efficacy and safety of lincomycin combined with ribavirin in the treatment of pediatric pneumonia. METHODS From July 2016 to July 2018,106 cases of pediatric pneumonia,depending on the condition of the child were divided into two groups,combined treatment group and simple treatment group( n = 53). The simple treatment group was treated with ribavirin.The combined treatment group was treated with lincomycin on the basis of the simple treatment group.Treatment for one week,the clinical efficacy,pulmonary function( FEV1/FVC,PEF,MBC),inflammatory index( IL-2,IL-6) and adverse reactions were observed in the two groups. RESULTS The total effective rate of the combined treatment group( 96. 4%) was significantly higher than that of the simple treatment group( 78. 6%). The FEV1/FVC,PEF and MBC of the combined treatment group were significantly higher than that of the simple treatment group( P < 0. 05),and the IL-2,IL-6 level of the combined treatment group was significantly lower than that of the simple treatment group. There were no adverse drug reactions such as nausea,headache,dry mouth,drowsiness and so on in both groups. CONCLUSION Lincomycin combined with ribavirin can effectively improve pulmonary function and eliminate inflammatory reaction in children with pneumonia.
OBJECTIVE To study the clinical efficacy and safety of lincomycin combined with ribavirin in the treatment of pediatric pneumonia. METHODS From July 2016 to July 2018,106 cases of pediatric pneumonia,depending on the condition of the child were divided into two groups,combined treatment group and simple treatment group( n = 53). The simple treatment group was treated with ribavirin.The combined treatment group was treated with lincomycin on the basis of the simple treatment group.Treatment for one week,the clinical efficacy,pulmonary function( FEV1/FVC,PEF,MBC),inflammatory index( IL-2,IL-6) and adverse reactions were observed in the two groups. RESULTS The total effective rate of the combined treatment group( 96. 4%) was significantly higher than that of the simple treatment group( 78. 6%). The FEV1/FVC,PEF and MBC of the combined treatment group were significantly higher than that of the simple treatment group( P < 0. 05),and the IL-2,IL-6 level of the combined treatment group was significantly lower than that of the simple treatment group. There were no adverse drug reactions such as nausea,headache,dry mouth,drowsiness and so on in both groups. CONCLUSION Lincomycin combined with ribavirin can effectively improve pulmonary function and eliminate inflammatory reaction in children with pneumonia.
引文
[1]朱晓华,李岚,陈晨,等.冬春季小儿肺炎感染病原分析[J].江西医药,2014,49(12):1356-1359.
[2]靳淑雁,刘世新,郑静,等.2012-2014年深圳市5岁以下小儿肺炎流行特征与病原学分析[J].实用预防医学,2016,23(6):701-704.
[3]姚永新.某院儿童肺炎链球菌感染耐药分析[J].今日药学,2014,24(4):296-298.
[4]吴跃进,孙节,张建华,等.糖皮质激素辅助治疗小儿肺炎支原体大叶性肺炎的疗效[J].中国当代儿科杂志,2014,16(4):401-405.
[5]江载芳,申昆玲.诸福棠实用儿科学(第8版)[M].北京:人民卫生出版社,2015:1253-1259.
[6]耿丽娟.利巴韦林联合氨溴索氧气雾化吸入治疗小儿肺炎的疗效观察[J].临床医学研究与实践,2016,38(3):54-55.
[7]唐辉英,李莉.糖皮质激素治疗小儿社区获得性支原体肺炎的疗效及安全性分析[J].临床医学,2016,36(2):94-95.
[8]王冰.吸入糖皮质激素治疗小儿肺炎支原体肺炎的疗效观察[J].临床肺科杂志,2016,20(8):1459-1461.
[9]刘江平,刘铁民,朱丹.喜炎平注射液联合利巴韦林注射液治疗小儿病毒性肺炎的疗效观察[J].中国医院用药评价与分析,2017,24(3):334-335,338.
[10]黄艳春,毛开新.喜炎平注射液联合利巴韦林静滴治疗小儿病毒性肺炎临床观察[J].山东医药,2015,47(31):58-59.
[11]王红连.小儿肺炎支原体肺炎发病状况与疾病负担的研究[J].临床肺科杂志,2015,20(7):1266-1269.
[12]梁锦枝,吴锗珊,罗钦宏,等.喜炎平联合阿奇霉素治疗支原体肺炎疗效的Meta分析[J].中国实验方剂学杂志,2014,23(18):220-224.
[13]Salwa R S,Samia M G,Noha N A,et al.Validated Spectrodensitometric Method for Simultaneous Estimation of Sofosbuvir,Ribavirin and Saxagliptin in their Pure and Pharmaceutical Dosage Forms[J].Current Pharmaceutical Analysis,2018,89(1):212-218.
[14]张涛,王波,王穗琼,等.小儿肺炎支原体的耐药性与临床用药相关性研究[J].中华妇幼临床医学杂志(电子版),2014,10(1):29-40.
[15]Dicpinigaitis P V,Dhar S,Johnson A,et al.Inhibition of cough reflex sensitivity by diphenhydramine during acute viral respiratory tract infection[J].Int J Clin Pharm,2015,37(3):471-474.
[16]邹汉金.炎琥宁联合利巴韦林治疗小儿病毒性肺炎的疗效及对炎症因子的影响[J].中国医药科学,2017,23(16):40-43.
[2]靳淑雁,刘世新,郑静,等.2012-2014年深圳市5岁以下小儿肺炎流行特征与病原学分析[J].实用预防医学,2016,23(6):701-704.
[3]姚永新.某院儿童肺炎链球菌感染耐药分析[J].今日药学,2014,24(4):296-298.
[4]吴跃进,孙节,张建华,等.糖皮质激素辅助治疗小儿肺炎支原体大叶性肺炎的疗效[J].中国当代儿科杂志,2014,16(4):401-405.
[5]江载芳,申昆玲.诸福棠实用儿科学(第8版)[M].北京:人民卫生出版社,2015:1253-1259.
[6]耿丽娟.利巴韦林联合氨溴索氧气雾化吸入治疗小儿肺炎的疗效观察[J].临床医学研究与实践,2016,38(3):54-55.
[7]唐辉英,李莉.糖皮质激素治疗小儿社区获得性支原体肺炎的疗效及安全性分析[J].临床医学,2016,36(2):94-95.
[8]王冰.吸入糖皮质激素治疗小儿肺炎支原体肺炎的疗效观察[J].临床肺科杂志,2016,20(8):1459-1461.
[9]刘江平,刘铁民,朱丹.喜炎平注射液联合利巴韦林注射液治疗小儿病毒性肺炎的疗效观察[J].中国医院用药评价与分析,2017,24(3):334-335,338.
[10]黄艳春,毛开新.喜炎平注射液联合利巴韦林静滴治疗小儿病毒性肺炎临床观察[J].山东医药,2015,47(31):58-59.
[11]王红连.小儿肺炎支原体肺炎发病状况与疾病负担的研究[J].临床肺科杂志,2015,20(7):1266-1269.
[12]梁锦枝,吴锗珊,罗钦宏,等.喜炎平联合阿奇霉素治疗支原体肺炎疗效的Meta分析[J].中国实验方剂学杂志,2014,23(18):220-224.
[13]Salwa R S,Samia M G,Noha N A,et al.Validated Spectrodensitometric Method for Simultaneous Estimation of Sofosbuvir,Ribavirin and Saxagliptin in their Pure and Pharmaceutical Dosage Forms[J].Current Pharmaceutical Analysis,2018,89(1):212-218.
[14]张涛,王波,王穗琼,等.小儿肺炎支原体的耐药性与临床用药相关性研究[J].中华妇幼临床医学杂志(电子版),2014,10(1):29-40.
[15]Dicpinigaitis P V,Dhar S,Johnson A,et al.Inhibition of cough reflex sensitivity by diphenhydramine during acute viral respiratory tract infection[J].Int J Clin Pharm,2015,37(3):471-474.
[16]邹汉金.炎琥宁联合利巴韦林治疗小儿病毒性肺炎的疗效及对炎症因子的影响[J].中国医药科学,2017,23(16):40-43.